Skip to main content
EJNMMI Research
Fig. 5 | EJNMMI Research

Fig. 5

From: Initial evaluation of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate (FSPG) PET/CT imaging in patients with head and neck cancer, colorectal cancer, or non-Hodgkin lymphoma

Fig. 5

Combined image set shows four representative subjects with non-Hodgkin lymphoma (NHL). Displayed from left to right are the axial CT (soft-tissue window shown at various cranio-caudal levels), [18F]FDG PET, and [18F]FSPG PET images. The first subject (row a) with diffuse large B cell lymphoma has a large soft-tissue mass in the right hip invading the bone, the second subject (row b) with follicular lymphoma has a large mesenteric lymph node on the left, the third subject (row c) with mantle cell lymphoma has small bilateral axillary lymph nodes, and subject 4 (row d) with mantle cell lymphoma has a large central mesenteric mass. The black arrows indicate the lesions. Any unmarked uptake on the PET scans is physiologic. The lesions are seen on all modalities, although the [18F]FSPG PET scan shows very little uptake for some of the lesions (SUV right hip mass (a) 11.3 and 2.9, left mesenteric lymph node (b) 9.2 and 3.2, right axillary lymph node (c) 3.5 and 1.1, and central mesenteric mass (d) 11.1 and 21.9, for [18F]FDG and [18F]FSPG, respectively)

Back to article page